Switzerland
• submission of MAA for an orphan biological product • responsible for orphan activities: orphan designation applications, maintenance reports & annual reports • responsible for paediatric activities: PIP modifications, request for waiver and compliance check • CHMP scientific advice
• managed EU CTAs : review of protocols & investigator’s brochures, preparation of core packages, DSUR submission
• responsible for lifecycle activities for a biologic product • managed CTAs for an ATMP for the Intercontinental region • developed the regulatory strategy for an early stage oncology product
• submitted MAAs, variations and renewals for the Intercontinental region
• prepared end of phase 2 & advisory committee meetings with FDA • led preparation of a global regulatory plan: strategic assessment for development across regions • conducted a gap analysis on drug/device combination products and created a tool to address internal gaps